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The extensive research conducted on monoaminergic systems
including dopaminergic, serotonergic, noradrenergic, histaminer-
gic and, to a lower extent melatonergic systems, continues to
expand our current knowledge. The topic has enormous health,
economic, scientiﬁc and conceptual stakes, with engagement
across disciplines covering medicinal chemistry to neuropsychiat-
ric and neurological diseases. This special issue presents scientiﬁc
updates with in depth analyses on selected aspects of this
complicated topic.
Antipsychotic and antidepressant drugs opened the way to
intensive research on monoaminergic systems. The serendipitous
discoveries of these treatments in the 1950s led to the identiﬁca-
tion of monoaminergic systems as the main origin of their efﬁcacy.
Under the scope of neurosciences and biological psychiatry, much
fundamental research has identiﬁed the proteins involved in the
function of monoaminergic systems. As illustrated on Fig. 1, each
monoamine can act on a variety of receptors distinctly expressed in
the brain, and displaying some selectivity for each monoamine.
While the picture roughly illustrates the main families of these
receptors, molecular biology has revealed the existence of several
subtypes for most of these receptors coming from alternative
splicing, posttranscriptional and/or posttranslational processes.
The identiﬁcation of speciﬁc monoaminergic targets involved in
the beneﬁcial and side effects of these drugs has enabled medicinal
chemistry to produce drugs favouring one or several good targets
over the deleterious ones. The article by Butini et al. is an
illustration of the pharmacological proﬁle and chemical require-
ments of new antipsychotic or anti-Parkinsonian drugs to achieve
good efﬁcacy with low or no side-effects (Butini et al., 2016).
Several receptors or enzymes are usually targeted leading to the
new popularity of multitarget drug design (Millan, 2009; Ramsay
et al., 2016; Weinreb et al., 2016).
The pharmacological proﬁle of a multi-target drug is even more
complicated because the molecular environment of one target is
speciﬁc to the cell expressing this target, leading to biased agonists.
This means that a drug behaves differently on its target depending
on the tissue. Interesting achievements have been obtained with
drugs preferentially activating somatodendritic 5-HT1A autore-
ceptors versus heteroreceptors and vice versa that could be
pertinent for the treatment of mood disorders or dyskinesia
induced by L-DOPA. While the speciﬁcations are growing for
producing newer drugs, the molecular pharmacology becomes
more insightful in conceptualizing the partnerships ofhttp://dx.doi.org/10.1016/j.pneurobio.2017.02.001
0301-0082/© 2017 Elsevier Ltd. All rights reserved.neurotransmitter receptors in space and time. Wirth et al. report
an interesting perspective of molecular signalling events in the
morphogenic effects of serotonin (5-HT) (Wirth et al., 2017). These
effects include a variety of 5-HT receptors that modulate
synaptogenesis, neurite outgrowth, dendritic spine shape and
density. These regulations occur at different stages of the
development, are region-dependent and could maintain aberrant
modelling of networks and pathophysiology.
The reﬁnement of pharmacological drugs has helped elucidate a
better understanding of the pathophysiology of numerous CNS
diseases. A better knowledge of pathophysiology is surely a step for
the identiﬁcation of new pharmacological targets, perhaps beyond
the symptomatic treatment (Millan et al., 2015). At a time where
the pathology-to-drug discovery approach is in expansion, our
certitudes regarding the treatment of Parkinson’s disease and the
mechanism of action of the lead antiparkinsonian treatment L-
DOPA are disappearing. The metabolic precursor of dopamine (DA),
L-DOPA is administered to patients soon after the identiﬁcation of
the loss of dopamine in the putamen and caudate nucleus of
Parkinson patients. De Deurwaerdère et al. have reported
numerous data dampening the idea that the beneﬁt and side
effects of L-DOPA were related to an increase in DA in the caudate
nucleus and the putamen (De Deurwaerdere et al., 2017). The
mechanisms of L-DOPA appear to be much more subtle,
widespread in the brain and distinct from dopaminergic agonists.
Referring again to Fig. 1, it is noteworthy that monoaminergic
systems share enzymes for their biosynthesis, the vesicular
monoamine transporter for their translocation into the vesicles
of exocytosis, enzymes for their catabolism as well transporters for
the reuptake. Some transporters and enzymes are also present in
neighbouring glial and neuronal cells. Consequently, the adminis-
tration of amino acid precursors such as L-DOPA or drugs that act
on degrading enzymes such as monoamine oxidase inhibitors can
only result in ectopic effects.
Serendipity has played an important role in the development of
drugs aimed at treating the symptoms of schizophrenia, mood
disorders or Parkinson’s disease. This point of view is further
stressed in considering that diseases like Alzheimer’s disease or
epilepsy still do not have monoaminergic-based treatments
(Di Giovanni et al., 2016; Svob Strac et al., 2016). The paper by
Simic et al. recalls that Alzheimer’s disease is also marked by
several perturbations of monoaminergic systems (Simic et al.,
2017). Hopefully, the numerous clinical trials they report with
monoaminergic drugs targeting neuroreceptors will end up soon
in a more appropriate medical care of the disease. The other side of
Fig. 1. Molecular organization of central monoaminergic systems.
The ﬁgure shows each monoamine system (dopamine, DA; noradrenaline, NA; serotonin, 5-HT; histamine); the biosynthesis, metabolism, the receptors and transporters.
Colors are used to identify the proteins that are selective for each system while the black color is used for non-speciﬁc proteins. The terminals of each monoaminergic neurons
contact post-synaptic elements in the brain that express a variety of receptors which are more or less speciﬁc for each monoamine. The main families are represented.
Autoreceptors can be located at terminals and cell bodies for most monoaminergic systems. In the case of serotonergic cells, 5-HT1A autoreceptors are addressed at cell bodies
and 5-HT1B autoreceptors are addressed at terminals; 5-HT2B autoreceptors would be addressed at both sites. The post-synaptic elements (neurons, glial cells) also express
enzymes involved in the metabolism of monoamines (MAO-A/B or COMT) as well as non-speciﬁc transporters. DBH is mainly expressed in vesicles of exocytosis in
noradrenergic terminals. AADC, aromatic L-amino acid decarboxylase; DBH, dopamine b-hydroxylase; TPH, tryptophan hydroxylase; VMAT2, vesicular monoamine
transporter; SERT, 5-HT transporter, DAT, DA transporter; NET, NA transporter; OCT, organic cation transporters; PMAT, plasma membrane monoamine transporter; HDC, L-
histidine decarboxylase; MAO, monoamine oxidase (A or B); COMT, catechol-O-methyl transferase.
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monoaminergic systems in the beneﬁt and side effects of
efﬁcacious therapies. Here, two articles by Faggiani and Benazzouz
and by Galati et al., focus on the impact of deep brain stimulation of
the subthalamic nucleus in the treatment of Parkinson’s disease
with speciﬁc regards on monoamines and on non-motor and motor
effects of the treatment, (Faggiani and Benazzouz, 2017; Stefani
et al., 2017), respectively. Numerous neurochemical effects are
triggered by the deep brain stimulation of the subthalamic nucleus
on monoaminergic systems but the extent to which these
modiﬁcations lead to therapeutic effects is still a matter of debate.At one point one may wonder why it is so difﬁcult to progress
and to understand the function of these systems. Maybe the
organization and the morphology of these systems is a real issue. In
fact, the cell bodies of these neurons are conﬁned in hypothalamus
(histamine), mesencephalon (DA, 5-HT), pons (5-HT) or medulla
(noradrenaline) and innervate widely the entire encephalon with
thousand sites of release for only one neuron. The neurohumoral
way of contacting neurobiological networks and long distance
neurons imply local and distal interactions. In addition, the
monoaminergic systems establish complex interactions in the
brain. De Deurwaerdère and Di Giovanni emphasise the interaction
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2017). Beyond the molecular and cellular complexity of the
mechanisms involved in the inﬂuence of 5-HT on DA neuronal
function, the authors highlight also the multiplicity of regions and
dimensions implicated in this interaction, which is important for
the mechanism of action of antipsychotic, antidepressant, anti-
Parkinsonian and anti-addictive drugs.
While there has been a lot of progress in molecular
pharmacology, it is also mandatory to progress on the physiological
roles of these monoaminergic systems in the brain. The
neuropharmacological approaches brought many indications
and still will bring more. Lorincz and Adamantidis in this issue
highlight the use of new technologies such as optogenetic
targeting speciﬁcally subsets of neurons, systems or receptors to
study the function of monoaminergic systems (Lorincz and
Adamantidis, 2017). These new approaches will shed another
light on monoaminergic systems to better understand the efﬁcacy
of various medicines used to treat CNS diseases.
The tale continues.
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